| Sep 5 |
Stockholders Vote to Elect Madhavan Balachandran to Board of Directors
|
| Sep 3 |
Replimune: Strong Data In A Highly Differentiated Space
|
| Aug 22 |
Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024
|
| Aug 14 |
Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy
|
| Aug 13 |
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
|
| Aug 8 |
Replimune Group GAAP EPS of -$0.78 beats by $0.09
|
| Aug 8 |
Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update
|
| Jul 30 |
Replimune to Present at Two Upcoming Investor Conferences
|
| Jun 13 |
Replimune to raise ~$100M in private financing
|
| Jun 13 |
Replimune Announces $100 Million Private Placement Financing
|
